- Conditions
- Dermatitis, Atopic
- Interventions
- GSK1070806, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 6
- States / cities
- Fountain Valley, California • Pompano Beach, Florida • Fayetteville, Georgia + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2233–2256
of 4,225
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Alport Syndrome
- Interventions
- lademirsen (SAR339375), Placebo
- Drug
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Minneapolis, Minnesota • New York, New York + 2 more
- Conditions
- Benign Prostatic Hyperplasia
- Interventions
- PRX302, Placebo
- Drug · Other
- Lead sponsor
- Sophiris Bio Corp
- Industry
- Eligibility
- 50 Years and older · Male only
- Enrollment
- 479 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 45
- States / cities
- Huntsville, Alabama • Anchorage, Alaska • Laguna Hills, California + 40 more
- Conditions
- Acute Pericarditis
- Interventions
- Anakinra, Placebo
- Drug
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Osteoarthritis of the Knee, Degenerative Osteoarthritis, Knee Pain Chronic
- Interventions
- Ibuprofen and PRP, Acetaminophen and PRP, Placebo and PRP
- Combination Product
- Lead sponsor
- QC Kinetix LLC
- Industry
- Eligibility
- 50 Years and older
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Charlotte, North Carolina
- Conditions
- Early Rheumatoid Arthritis
- Interventions
- Adalimumab, Methotrexate, Adalimumab placebo, Methotrexate placebo
- Biological · Drug
- Lead sponsor
- AbbVie (prior sponsor, Abbott)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 799 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2012
- U.S. locations
- 31
- States / cities
- Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 24 more
- Conditions
- Muscular Dystrophy, Duchenne
- Interventions
- MNK-1411, Placebo
- Drug · Other
- Lead sponsor
- Mallinckrodt ARD LLC
- Industry
- Eligibility
- 4 Years to 8 Years · Male only
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 5
- States / cities
- Gulf Breeze, Florida • Atlanta, Georgia • Nashville, Tennessee + 2 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Abatacept, Methotrexate, Abatacept Placebo, Methotrexate Placebo
- Drug · Other
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 994 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 42
- States / cities
- Huntsville, Alabama • Glendale, Arizona • Mesa, Arizona + 36 more
- Conditions
- Painful Lumbar Radiculopathy, Sciatica, Radiculopathy
- Interventions
- BG00010, Placebo
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 183 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Fresno, California • Lomita, California + 22 more
- Conditions
- COVID-19 (Healthy Volunteers)
- Interventions
- CoV2 preS dTM-AF03 (low-dose), CoV2 preS dTM-AF03 (high-dose), CoV2 preS dTM-AS03 (low-dose), CoV2 preS dTM-AS03 (high-dose), CoV2 preS dTM (high-dose) without adjuvant, Placebo (0.9% normal saline)
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 441 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Rolling Hills Estates, California • Hollywood, Florida + 7 more
- Conditions
- Type 2 Diabetes, Glucose Tolerance Impaired, Insulin Sensitivity
- Interventions
- REMD-477, Placebo Subcutaneous injection
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)
- Interventions
- Dupilumab SAR231893 (REGN668), Placebo, Mometasone furoate 50 micrograms
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 276 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 18
- States / cities
- Long Beach, California • Orange, California • San Diego, California + 15 more
- Conditions
- Type 2 Diabetes
- Interventions
- XOMA 052, Placebo
- Drug
- Lead sponsor
- XOMA (US) LLC
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 4
- States / cities
- Escondido, California • Miami Gardens, Florida • Omaha, Nebraska + 1 more
- Conditions
- Rett Syndrome
- Interventions
- NNZ-2566, Placebo
- Drug
- Lead sponsor
- Neuren Pharmaceuticals Limited
- Industry
- Eligibility
- 16 Years to 45 Years · Female only
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Saint Paul, Minnesota • Houston, Texas
- Conditions
- Overweight, Obesity
- Interventions
- NNC0174-0833, Placebo (NNC0174-0833), Liraglutide 3.0 mg, Placebo (Liraglutide 3.0 mg)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 706 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 22
- States / cities
- Anaheim, California • Spring Valley, California • Crystal River, Florida + 19 more
- Conditions
- Osteoarthritis, Knee
- Interventions
- Placebo, CNTX-4975-05
- Drug
- Lead sponsor
- Centrexion Therapeutics
- Industry
- Eligibility
- 40 Years to 95 Years
- Enrollment
- 332 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 30
- States / cities
- Glendale, Arizona • Phoenix, Arizona • Carmichael, California + 23 more
- Conditions
- Osteoarthritis of the Hip
- Interventions
- Ropivacaine, Saline
- Drug
- Lead sponsor
- The Christ Hospital
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- Interventions
- Pemvidutide, Placebo
- Drug · Other
- Lead sponsor
- Altimmune, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1,800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 9
- States / cities
- North Little Rock, Arkansas • Fountain Valley, California • Fresno, California + 6 more
- Conditions
- Central Centrifugal Cicatricial Alopecia
- Interventions
- Platelet-Rich Plasma (PRP) Injections, Saline
- Biological · Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Giant Cell Arteritis
- Interventions
- Guselkumab, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 2
- States / cities
- Kansas City, Kansas • Boston, Massachusetts
- Conditions
- Human Metapneumovirus and Human Parainfluenza Infection
- Interventions
- mRNA-1653, Placebo
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 12 Months to 49 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2022
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Washington D.C., District of Columbia • Idaho Falls, Idaho + 16 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Double-blind Abatacept, Double-blind Placebo, Open-label Abatacept
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,795 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2009
- U.S. locations
- 44
- States / cities
- Decatur, Alabama • Paradise, Arizona • Phoenix, Arizona + 41 more
- Conditions
- Sepsis, Bronchopulmonary Dysplasia, Necrotizing Enterocolitis, Retinopathy of Prematurity, Systemic Inflammatory Response Syndrome
- Interventions
- Parenteral cysteine-HCl supplementation, Placebo - added premasol
- Dietary Supplement
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- Up to 30 Days
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Microvascular Coronary Artery Disease
- Interventions
- SAR407899, Placebo, Adenosine, Regadenoson, 13N-ammonia, 82Rubidium
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Jacksonville, Florida • Wellington, Florida + 3 more